New procedure could help stroke patients whose symptoms worsen

NCT ID NCT07557485

Not yet recruiting Disease control Sponsor: Feng Gao Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a minimally invasive procedure called endovascular treatment can help people who have a progressive stroke caused by a blockage in the main artery at the back of the brain. The procedure uses a catheter to remove or open the clot. The trial will include 240 adults whose stroke symptoms worsen within 24 hours to 14 days after the first signs. The main goal is to see if more patients can live independently (able to walk without help) 90 days after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Endovascular recanalization (a procedure using catheters to remove or open blood clots in the brain)
What this could lead to: If successful, this procedure could become a standard treatment to reduce disability after a progressive stroke caused by a blockage in the back of the brain.
What could go wrong: This is a relatively small, early-stage trial (240 participants) and the procedure carries risks like bleeding, vessel damage, or failed clot removal. Results may not apply to all stroke patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOVASCULAR TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basilar artery occlusion Ischemic Stroke vertebral artery occlusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOVASCULAR TREATMENT VERTEBROBASILAR ARTERY OCCLUSION

Contacts and locations

Locations

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.